ライフサイエンスコーパス: PCV

1 PCV coverage was assessed from the Australian Childhood

2 PCV failure is rare and, compared to PCV7 serotypes, the

3 PCV impact on ANSP nasopharyngeal carriage is a dynamic,

4 PCV patients on pro re nata (PRN) anti-vascular endothel

5 PCV performance was highly dependent on the circulating

6 PCV serotype carriage declined by 80%, while that of non

7 Data on impact of a timely 3 + 0 PCV schedule with high coverage are sparse, with none fo

8 re all infected with Pepper cryptic virus 1 (PCV-1; family Partitiviridae).

9 A total of 364 patients (165 AMD and 199 PCV) were included.

10 emonstrate real-world effectiveness of 2p+1b PCV dosing against vaccine-serotype colonization.

11 9), during (2010-2011) and after (2012-2015) PCV introduction.

12 catalyst to produce synzyme protocells (Ru(4)PCVs) with catalase-like activity.

13 idual horseradish peroxidase-containing Ru(4)PCVs, and chemical signalling in distributed or encapsul

14 .1% relative reduction from 19.9% to 16.7%); PCV-unvaccinated children 6-8-year-old (40.5% reduction

15 reports from high-income countries giving a PCV booster dose.

16 We found that expanding infant-administered PCV valency is likely to result in diminishing returns,

17 f age at various timepoints before and after PCV doses and analysed (in a blinded manner) by ELISA an

18 ncy room in southern Israel before and after PCV implementation.

19 ncy room in southern Israel before and after PCV implementation.

20 ococcal pneumonia incidence before and after PCV introduction in Kenya in 2011.

21 IPD incidences declined after PCV introduction in both immunocompetent and iatrogenica

22 ed decrease in pneumococcal meningitis after PCV introduction may be indicative of changing patterns

23 ine serotypes among children and women after PCV introduction.

24 44.4% in 2011 to 0.0% in 2014, 5 years after PCV implementation.

25 igh residual VT carriage 3.6-7.1 years after PCV introduction.

26 bility was significantly more frequent among PCV serotypes than among non-PCV serotypes and among Bed

27 This includes among PCV-vaccinated children 3-5-year-old (16.1% relative red

28 rriage prevalence half-life is similar among PCV-vaccinated and PCV-unvaccinated children (3.26 and 3

29 munized with DTaP (41% vs 89%, P < .001) and PCV (59% vs 79%, P = .008).

30 d number of intravitreal injections (AMD and PCV adjusted odds ratio, 12.1 [P = 0.001] and 12.5 [P =

31 e of resolution (logMAR) letters for AMD and PCV patients, respectively.

32 Patients with AMD and PCV received 5.5 and 5.3 injections (5.0 monotherapy vs.

33 study included patients with typical AMD and PCV who received anti-VEGF therapy over a 12-month perio

34 djusted odds ratio, 3.8 and 10.6 for AMD and PCV, respectively).

35 g the incidence rate between the pre-PCV and PCV periods for Israel, South Africa, and the USA.

36 months postvaccination, GMCs to TT, PT, and PCV serotypes increased from baseline (P < .001 for all

37 alf-life is similar among PCV-vaccinated and PCV-unvaccinated children (3.26 and 3.34 years, respecti

38 Here we assess PCV carriage using rolling, prospective nasopharyngeal c

39 ness was not significantly different between PCV and typical AMD eyes, and was thicker in the study e

40 o impute the indirect protection afforded by PCV in unvaccinated age groups, including those in high-

41 nce interval [CI], .50-.57), but differed by PCV era.

42 eumococcal, many can in fact be prevented by PCVs.

43 dered pneumococcal, many can be prevented by PCVs.

44 dered pneumococcal, many can be prevented by PCVs.Pneumococcal conjugate vaccine (PCV7/PCV13) impleme

45 , treatment with postradiation chemotherapy (PCV; procarbazine, lomustine (CCNU), and vincristine) wa

46 Childhood PCV programs have provided considerable benefit, with su

47 D incidence prior to and following childhood PCV immunization in South Africa.

48 INTERPRETATION: Population childhood PCV programmes will lead, on average, to substantial pro

49 Among children, PCV-conferred protection against CAAP attributable to va

50 d in comparison to other vaccines, continued PCV use at full costs is cost-effective (on the basis of

51 Continuing PCV after 2022 will require an estimated additional US$1

52 Continuing PCV use is essential to sustain its health gains.

53 and related mortality for either continuing PCV use beyond 2022, the start of Kenya's transition fro

54 incremental cost-effectiveness of continuing PCV use.

55 remental cost per DALY averted of continuing PCV would be $153 (95% PI 70-411) in 2032.

56 The aim of this study was to determine PCV impact on the prevalence of serotypes, genetic linea

57 aimed to assess the performance of differing PCV schedules against vaccine-serotype colonization in c

58 ine (PCV) use at full cost or to discontinue PCV in their childhood immunisation programmes.

59 After 9 years of timely 3-dose PCV coverage of >92%, all-age IPD in Australia almost ha

60 Pneumococcal genomic surveys elucidate PCV effects on population structure but are rarely condu

61 lance of colonization prior to and following PCV use can be used to impute the indirect protection af

62 asive pneumococcal disease changes following PCV introduction in unvaccinated populations, updating t

63 even after reported cases declined following PCV introduction.

64 neumonia declined in western Kenya following PCV introduction, likely reflecting vaccine indirect eff

65 ges in vaccine-type Spn meningitis following PCV introduction.

66 In contrast, for PCV eyes, anti-VEGF monotherapy and combination therapy

67 alysis assembling the available evidence for PCV impact on European, North American and Australian na

68 r PCV with monotherapy, and 35.5 letters for PCV with combination therapy).

69 ment (10.4 letters for AMD, 17.1 letters for PCV with monotherapy, and 35.5 letters for PCV with comb

70 e alternative to the traditional process for PCV development.

71 PCV-13 serotypes and enhances protection for PCV-13 serotypes when coadministered with PCV-13.

72 gs highlight the value of Gavi's support for PCV introduction in low-income countries and of efforts

73 ng the advantages of combination therapy for PCV.

74 umococcal polysaccharide vaccine or a fourth PCV dose in the case of graft-versus-host disease (GvHD)

75 l polysaccharide vaccine (PSV23) or a fourth PCV dose in the case of graft-versus-host disease (GvHD)

76 We compared the effect of odor cues from PCV-1-infected (J+) and virus-free (J-) jalapeno peppers

77 The Gambian PCV programme reduced the incidence of invasive pneumoco

78 elp to predict the impact of next-generation PCVs in specific risk groups.

79 e of herd protection is critical for guiding PCV policy decisions in resource-constrained areas.

80 e during the preceding period of heptavalent PCV (PCV7) use, overall and by serotype category.

81 However, PCVs are among the most expensive vaccines, hindering th

82 In the present study, we identified PCVs expected to minimize the post-vaccine IPD burden by

83 We predicted that if PCV use is discontinued in Kenya in 2022, overall IPD in

84 In PCV on PRN anti-VEGF therapy, increases in PED area and

85 IPD cases in PCV-eligible children aged <5 years (born since 4 Septem

86 ates were similar to the observed changes in PCV-unvaccinated children and adults, but not among chil

87 often infected by serotypes not included in PCV (69% vs 31%; P < .001).

88 coccal disease (IPD) due to the reduction in PCV serotypes.

89 g, 15A and 35B) not currently represented in PCV formulations increased modestly.

90 omarker to predict the treatment response in PCV.

91 al because of the expectation that increased PCV use will substantially reduce the burden of pneumoni

92 in a 2 + 1 schedule (group E); or no infant PCV (control; group F).

93 omputer-generated list, to one of six infant PCV schedules: PCV10 in a 3 + 1 (group A), 3 + 0 (group

94 njugate vaccine (PCV13) is the only licensed PCV with serotype 3 polysaccharide in its formulation.

95 Licensed PCVs currently cover only 13 of the over 90 serotypes of

96 l review of 38 consecutive PDT-naive macular PCV patients who underwent verteporfin PDT using one of

97 a 1 + 1 schedule in countries with a mature PCV programme and established herd immunity is likely to

98 We measured PCV-conferred protection against CAAP attributable to va

99 We measured PCV-conferred protection against carriage of vaccine-ser

100 2 eyes from 29 patients with treatment naive PCV and 30 eyes from 30 healthy control participants wer

101 Among non-PCV isolates, the proportion of ANSP significantly incre

102 frequent among PCV serotypes than among non-PCV serotypes and among Bedouin children than among Jewi

103 ypoidal choroidal vasculopathy (PCV) and non-PCV subtypes.

104 es remain stable owing to replacement by non-PCV serotypes.

105 inst pneumococcal acute otitis media for non-PCV-13 serotypes and enhances protection for PCV-13 sero

106 carriage declined by 80%, while that of non-PCV serotypes increased by 140%.

107 reduction of PCV serotypes, increase of non-PCV serotypes, potential overall reduction in carriage,

108 PFS or OS was observed with the addition of PCV in the IDH-wild-type subgroup.

109 status receive benefit from the addition of PCV.

110 The appearance of PCV lesions on multicolor imaging differs from standard

111 se results demonstrate a 3-D architecture of PCV that may be helpful for a better understanding of th

112 ction studies have estimated the benefits of PCV use on childhood mortality and results have been inc

113 The expected cost of PCV vaccination globally is around $16 billion per year.

114 Choroidal vascular density (CVD) of PCV eyes was higher than normal eyes in majority regions

115 inal specialists to confirm the diagnosis of PCV and identify lesion components.

116 l patients had received at least one dose of PCV and were assessed for antipneumococcal immunoglobuli

117 l patients had received at least one dose of PCV and were assessed for antipneumococcal immunoglobuli

118 Data are scarce for the effect of PCV in the Asia and Pacific region.

119 gh-income settings) to predict the effect of PCV on childhood invasive pneumococcal disease, and a de

120 sia and Pacific region to show the effect of PCV on pneumonia, filling gaps in the literature on the

121 as measured as an indicator of the effect of PCV-1 on host quality for aphids.

122 ict the direct and indirect effectiveness of PCV by analyzing serotype-specific colonization prevalen

123 A total of 163 episodes of PCV failure were confirmed in 161 children over 8 years

124 We aimed to describe the features of PCV detected using multicolor imaging and to compare the

125 The features of PCV seen on multicolor imaging have not been studied.

126 INTERPRETATION: The introduction of PCV in The Gambia was associated with a moderate impact

127 assess this burden following introduction of PCV-13 in a nationwide cohort study.

128 is in children shortly after introduction of PCV-13 remained substantial.

129 During follow-up, there was no occurrence of PCV.

130 hing vascular networks (BVNs), and origin of PCV using optical coherence tomography angiography (OCTA

131 However, the underlying pathogenesis of PCV is still yet to be fully elucidated, and the correla

132 ability, supporting that the pathogenesis of PCV may include choroidal congestion and dilatation.

133 natomy, pathophysiology, and pathogenesis of PCV.

134 The prevalence of PCV was determined in each group based on ICGA.

135 understand the pathogenesis and prognosis of PCV by quantitatively evaluating choroidal vasculature f

136 cus pneumoniae (ANSP) carriage: reduction of PCV serotypes, increase of non-PCV serotypes, potential

137 roidal vasculature and treatment response of PCV are poorly understood.

138 ive adjunct to detect features suggestive of PCV, which may prompt definitive investigations such as

139 to standard-fluence PDT in the treatment of PCV in terms of visual gains, clinical and anatomical OC

140 The real-world outcomes for treatment of PCV showed larger gains in vision, higher proportion of

141 nfectious disease in New Zealand, the use of PCV appears associated with reductions in ethnic and soc

142 d of efforts to improve the affordability of PCVs in countries not eligible for, or transitioning fro

143 ffset a greater proportion of the benefit of PCVs in strata in which the NVTs comprised a larger prop

144 ble for maintaining the indirect benefits of PCVs.

145 magnitude and timing of indirect effects of PCVs on invasive pneumococcal disease.

146 ile consistent with historical experience of PCVs in this age group.

147 A key question is whether the impact of PCVs on pneumonia is similar in low- and high-income pop

148 erent risk groups before the introduction of PCVs.

149 These data support decision making on PCV introduction for other low-income and middle-income

150 ggests a limited effect of current pediatric PCVs against IPD in the elderly.

151 15 years post PCV and 5 years post PCV13, direct and indirect impact o

152 differed between the pre-PCV period and post-PCV era.

153 Between the pre-PCV and post-PCV eras, the prevalence of S. pneumoniae bacteremia dro

154 ing to carriage data from 2001/2002 and post-PCV IPD data to 2015, using vaccine coverage, mixing pat

155 e relative invasiveness of the pre- and post-PCV-carried pneumococcal populations.

156 penicillin-resistant lineages decreased post-PCV.

157 In each post-PCV year (2012-2016), the incidence was significantly lo

158 cteriocins, showed changes in frequency post-PCV.

159 Pre-PCV IPD data and pre-/post-PCV colonization data were modelled to estimate vaccine

160 of significant population restructuring post-PCV driven by decreasing frequency of vaccine serotypes

161 idual VTs and replacement NVT serotypes post-PCV.

162 serotypes (VTs) decreased significantly post-PCV, but no significant changes occurred in persons >=5

163 ve been recently shown to remain stable post-PCV due to replacement serotypes, there was no change in

164 ses due to pneumococcus declined in the post-PCV era.

165 The post-PCV implementation dynamics of these components were exa

166 Fifteen years post-PCV and 5 years post-PCV13, direct and indirect impact o

167 Pre-PCV (2008-2010) crude and adjusted ARI incidences were 3

168 Pre-PCV IPD data and pre-/post-PCV colonization data were mo

169 ed child-mother dyads from 2007 to 2009 (pre-PCV era), in 2010 (7-valent PCV era), and in 2012 (13-va

170 comparing the PCV13 (2014-2017) with the pre-PCV (2004-2008) periods.

171 comparing the incidence rate between the pre-PCV and PCV periods for Israel, South Africa, and the US

172 Between the pre-PCV and post-PCV eras, the prevalence of S. pneumoniae b

173 ; 95% CI, .61-1.61) differed between the pre-PCV period and post-PCV era.

174 1) in the PCV13 period compared with the pre-PCV period.

175 (IRRs) comparing PCV13 (2014-2017) with pre-PCV (2004-2008) periods were calculated.

176 cing IPD in global populations than previous PCVs.

177 metric mean concentrations (GMCs) to TT, PT, PCV serotypes, and varicella were lower in postchemother

178 uthern Israel, where children should receive PCV at ages 2 months, 4 months, and 12 months (2 primary

179 uthern Israel, where children should receive PCV at ages 2m, 4m, and 12m (2p+1b schedule).

180 duce pneumococcal disease in these settings, PCVs with broader serotype coverage and potency to reduc

181 >=0.35 ug/mL were maintained for 8/10 shared PCV serotypes in > 75% of children vaccinated with eithe

182 d to describe children who died of IPD since PCV introduction in England and Wales.

183 r herd effects of vaccination, dose-specific PCV effectiveness against colonization endpoints is not

184 e, with potential implications for long-term PCV impact in comparable settings.

185 e, with potential implications for long-term PCV impact in comparable settings.

186 e, with potential implications for long-term PCV impact in comparable settings.Fifteen years after pn

187 the national level was modest, we found that PCV led to larger reductions in low-income municipalitie

188 These results suggest that PCVs have an important impact on hospitalizations for al

189 Although the PCV-associated reduction in childhood pneumonia mortalit

190 Major pneumococcal lineages in the PCV period were identified by pooled incidence rate usin

191 that, with the current mature status of the PCV programme in England and Wales, removing one primary

192 ns were linked to evaluate the impact of the PCV vaccination program on cases of invasive pneumococca

193 ared the trajectory of decline of IPD due to PCV-targeted serotypes in adults with the decline of col

194 Prior to PCV introduction, at least 53% of pneumonia cases were d

195 Twenty-two PCV patients (mean age 69.6 years) were included.

196 es determine pneumococcal conjugate vaccine (PCV) antibiotic-nonsusceptible Streptococcus pneumoniae

197 hildren with pneumococcal conjugate vaccine (PCV) disrupts transmission, reducing disease rates in un

198 g 3 doses of pneumococcal conjugate vaccine (PCV) followed by either a dose of 23-valent pneumococcal

199 ree doses of pneumococcal conjugate vaccine (PCV) followed by either a dose of pneumococcal polysacch

200 pread use of pneumococcal conjugate vaccine (PCV) has brought about a dramatic decrease in pneumococc

201 Pneumococcal conjugate vaccine (PCV) implementation has led to a sharp decrease in invas

202 ed following pneumococcal conjugate vaccine (PCV) implementation.

203 eumococcal polysaccharide conjugate vaccine (PCV) in 2000 before it was expanded in subsequent years.

204 e benefit of pneumococcal conjugate vaccine (PCV) in protecting against invasive pneumococcal disease

205 Data on pneumococcal conjugate vaccine (PCV) indirect effects in low-income countries with high

206 years after pneumococcal conjugate vaccine (PCV) introduction and 5 years post-PCV13, direct and ind

207 Following pneumococcal conjugate vaccine (PCV) introduction in 2011, annual suspected meningitis c

208 is following pneumococcal conjugate vaccine (PCV) introduction.

209 re and after pneumococcal conjugate vaccine (PCV) introductions and were from children younger than 3

210 nd 13-valent pneumococcal conjugate vaccine (PCV) introductions worldwide.

211 Universal pneumococcal conjugate vaccine (PCV) programs began in Indigenous Australian children in

212 Universal pneumococcal conjugate vaccine (PCV) programs began in Indigenous Australian children in

213 Reduced-dose pneumococcal conjugate vaccine (PCV) schedules are under consideration in countries wher

214 Reduced-dose pneumococcal conjugate vaccine (PCV) schedules are under consideration in countries wher

215 reduction of pneumococcal conjugate vaccine (PCV) serotypes, from 44.4% in 2011 to 0.0% in 2014, 5 ye

216 to continue pneumococcal conjugate vaccine (PCV) use at full cost or to discontinue PCV in their chi

217 introducing pneumococcal conjugate vaccine (PCV).

218 d introduced pneumococcal conjugate vaccine (PCV)7 in June 2008, PCV10 in 2011, and PCV13 in 2014.

219 Pneumococcal conjugate vaccines (PCV) are highly protective against invasive pneumococcal

220 h childhood pneumococcal conjugate vaccines (PCV) can indirectly reduce illness in unvaccinated popul

221 e impact of pneumococcal conjugate vaccines (PCV) on burden of pneumococcal sepsis in children are la

222 onferred by pneumococcal conjugate vaccines (PCVs) against pediatric pneumonia attributable to vaccin

223 Pneumococcal conjugate vaccines (PCVs) are being used worldwide.

224 Pneumococcal conjugate vaccines (PCVs) are highly effective in preventing invasive pneumo

225 Pneumococcal conjugate vaccines (PCVs) are used in many low-income countries but their im

226 y effective pneumococcal conjugate vaccines (PCVs) are used in national immunization programs in many

227 t protein-polysaccharide conjugate vaccines (PCVs) generally induces immunity specific to one of the

228 oduction of pneumococcal conjugate vaccines (PCVs) has shown a marked reduction in the disease caused

229 oduction of pneumococcal conjugate vaccines (PCVs) has substantially reduced disease burden due to St

230 rollout of pneumococcal conjugate vaccines (PCVs) have exceeded predictions of vaccine impact.

231 Pneumococcal conjugate vaccines (PCVs) have had a well-documented impact on the incidence

232 Pneumococcal conjugate vaccines (PCVs) have reduced pneumococcal diseases globally.

233 Pneumococcal conjugate vaccines (PCVs) have significantly decreased pneumococcal disease

234 oduction of pneumococcal conjugate vaccines (PCVs) in five countries in the Americas.

235 g impact of pneumococcal conjugate vaccines (PCVs) in regions with high pneumococcal transmission is

236 ncerns that pneumococcal conjugate vaccines (PCVs) in sub-Saharan Africa sub-optimally interrupt Stre

237 oduction of pneumococcal conjugate vaccines (PCVs) into childhood vaccination programs has reduced ca

238 nation with pneumococcal conjugate vaccines (PCVs) is unknown.

239 d effect of pneumococcal conjugate vaccines (PCVs) on pneumonia mortality is crucial because of the e

240 oduction of pneumococcal conjugate vaccines (PCVs), before (2005- 2009), during (2010-2011) and after

241 y available pneumococcal conjugate vaccines (PCVs), ten-valent PCV (PCV10) and 13-valent PCV (PCV13).

242 en, and the pneumococcal conjugate vaccines (PCVs), which target only a fraction of the strains in th

243 oduction of pneumococcal conjugate vaccines (PCVs).

244 Pneumococcal conjugated vaccines (PCVs) impact on complex otitis media (OM; including recu

245 ured the effects of introducing high-valency PCVs on the incidence of invasive pneumococcal disease i

246 We examined the effect of 10-valent PCV on the incidence of pneumonia in Kenya.

247 The 10-valent PCV was introduced in Iceland in 2011.

248 of 16) before the introduction of 13-valent PCV (2010-2012) to 40.0% (8 of 20) after its introductio

249 ugates of serotypes present in the 13-valent PCV (PCV13) and 7 new serotypes (8, 10A, 11A, 12F, 15B,

250 ng infants who received 3 doses of 13-valent PCV (PCV13) and their mothers 5 years (CSS3) after PCV13

251 itional serotypes contained in the 13-valent PCV (PCV13) but not in PCV7.

252 e-specific 7-valent PCV (PCV7) and 13-valent PCV (PCV13) effectiveness against vaccine-serotype colon

253 Sp2 IPD outbreak in Israel, in the 13-valent PCV (PCV13) era, with focus on Sp2 population structure

254 d its clinical presentations after 13-valent PCV (PCV13) implementation.

255 cine (PCV7) from 2005, replaced by 13-valent PCV (PCV13) in 2011, uniquely among high-income countrie

256 all children in 2005, changing to 13-valent PCV (PCV13) in 2011.

257 from healthy carriers 2 years from 13-valent PCV (PCV13) introduction and 1 year after rollout in nor

258 IPD in countries with established 13-valent PCV (PCV13) programs.

259 t-effectiveness of introduction of 13-valent PCV (PCV13) vaccination globally.

260 uctions of 7-valent PCV (PCV7) and 13-valent PCV (PCV13) were associated with declines in IPD rates i

261 (PCVs), ten-valent PCV (PCV10) and 13-valent PCV (PCV13).

262 ineage as vaccine-type GPSC (>=50% 13-valent PCV [PCV13] serotypes) or non-vaccine-type GPSC (>50% no

263 0 (7-valent PCV era), and in 2012 (13-valent PCV era).

264 crease in IPD after 7-valent, then 13-valent PCV implementation, the spectrum of the remaining IPD ca

265 ningitis after the introduction of 13-valent PCV in Ghana.

266 with a further reduction following 13-valent PCV introduction from April 2010 to 0.39/100000 in 2013-

267 A 20-valent PCV (PCV20) containing capsular polysaccharide conjugate

268 eipt, we measured schedule-specific 7-valent PCV (PCV7) and 13-valent PCV (PCV13) effectiveness again

269 Although the introductions of 7-valent PCV (PCV7) and 13-valent PCV (PCV13) were associated wit

270 r age-specific total IPD, PCV13 non-7-valent PCV (PCV7) serotypes, and PnCAP by Indigenous status.

271 tion with the historical risk after 7-valent PCV (PCV7) vaccination and using chart-validation.

272 7-valent PCV (PCV7)/PCV13 vaccines were introduced in July 2009 a

273 es to describe the impact on IPD of 7-valent PCV (PCV7; introduced in 2006) and PCV13 (introduced in

274 007 to 2009 (pre-PCV era), in 2010 (7-valent PCV era), and in 2012 (13-valent PCV era).

275 lated mortality rate declined after 7-valent PCV introduction from 1.25/100000 children in 2006-2007

276 uped serotypes contained in the seven-valent PCV (PCV7), and 9.5 years (6.1-16.6) for the grouped six

277 l validated with data from post-seven-valent PCV introduction in 13 high-income settings) to predict

278 coccal conjugate vaccines (PCVs), ten-valent PCV (PCV10) and 13-valent PCV (PCV13).

279 ne (PCV13) alone and four use the ten-valent PCV (PCV10) and PCV13.

280 ce initiated at the time of 7- and 13-valent PCVs (PCV7; PCV13) implementation.

281 ue and UK prescribed concentration or value (PCV) for arsenic of 10 mug/L in 5% of properties surveye

282 according polypoidal choroidal vasculopathy (PCV) and non-PCV subtypes.

283 Polypoidal choroidal vasculopathy (PCV) is a common choroidal vascular disease particularly

284 Polypoidal choroidal vasculopathy (PCV) is a variant of neovascular age-related macular deg

285 r AMD and polypoidal choroidal vasculopathy (PCV) over 12-months.

286 atment in polypoidal choroidal vasculopathy (PCV).

287 enesis of polypoidal choroidal vasculopathy (PCV).

288 atment of polypoidal choroidal vasculopathy (PCV).

289 bounded polyoxometalate coacervate vesicles (PCVs) in the presence of a bio-inspired Ru-based polyoxo

290 Similarly, large benefits might occur when PCVs are introduced in other low-income settings.

291 Whereas PCV-derived protection against vaccine-serotype coloniza

292 letters after 12 months (P = 0.002), whereas PCV patients gained 6.6 logMAR letters (P = 0.001) and 1

293 fter adjusting for multiple factors, whereas PCV subtype was associated with better VA at month 12.

294 Patients in whom PCV was identified on OCTA were examined to define chara

295 or PCV-13 serotypes when coadministered with PCV-13.

296 e uptake and prevalence of colonization with PCV-targeted serotypes were obtained from children visit

297 Sixteen (26%) of 62 children up to date with PCV immunization presented with vaccine failure, includi

298 vaccine serotype in children up to date with PCV immunization was defined as vaccine failure.

299 Patients with PCV were younger (67.6 vs 72.5 years, P < .01) and recei

300 ect polypoidal lesions in most patients with PCV.